vTv Therapeutics (VTVT) to Release Earnings on Tuesday

vTv Therapeutics (NASDAQ:VTVT) is expected to be issuing its results before the market opens on Tuesday, November 11th. Analysts expect the company to announce earnings of ($0.97) per share for the quarter.

vTv Therapeutics (NASDAQ:VTVT) last posted its quarterly earnings results on Tuesday, August 12th. The biotechnology company reported ($0.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.07).

vTv Therapeutics Trading Up 0.5%

vTv Therapeutics stock traded up $0.13 during mid-day trading on Tuesday, reaching $23.53. The company had a trading volume of 2,032 shares, compared to its average volume of 10,988. vTv Therapeutics has a fifty-two week low of $12.62 and a fifty-two week high of $26.99. The company has a market cap of $92.64 million, a P/E ratio of -7.54 and a beta of 0.67. The business has a fifty day simple moving average of $20.88 and a 200 day simple moving average of $18.46.

Analyst Ratings Changes

A number of analysts have weighed in on VTVT shares. Weiss Ratings restated a “sell (d-)” rating on shares of vTv Therapeutics in a research report on Tuesday, October 14th. HC Wainwright reissued a “buy” rating and issued a $36.00 price objective on shares of vTv Therapeutics in a research note on Wednesday, August 13th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $35.50.

vTv Therapeutics Company Profile

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.